XSXiuhtlaulli López Suástegui

Xiuhtlaulli López Suástegui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiuhtlaulli López Suástegui has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trauma-Induced Coagulopathy: Mechanisms, Monitoring and Clinical Pearls in Critical Care

    by Xiuhtlaulli López Suástegui, Alejandro Rivera Mora

    Trauma-induced coagulopathy (TIC) is an early and clinically relevant disturbance of hemostasis that develops after severe injury and is closely associated with major hemorrhage, transfusion requirements, organ failure, and death. In this chapter, we review TIC from a practical critical care perspective, linking underlying mechanisms with bedside monitoring and treatment. We discuss conventional coagulation tests, viscoelastic assays, damage control resuscitation, balanced transfusion, fibrinogen and calcium replacement, tranexamic acid, and individualized hemostatic support, while highlighting clinical pearls, common pitfalls, and future directions relevant to everyday practice.

  • Open Access

    Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis

    by Han Naung Tun, May Thu Kyaw, Erik Rafflenbeul, Xiuhtlaulli López Suástegui

    Venous thromboembolism (VTE) is one of the leading causes of post-operative morbidity and mortality. Over previous decades, heparin and warfarin were the predominant therapeutic options for post-operative thromboprophylaxis. However, their use is limited by drawbacks including a narrow therapeutic range, numerous food and drug interactions, and the need for regular monitoring for dose adjustments. Recently, direct oral anticoagulants (DOACs), such as dabigatran etexilate (a direct thrombin inhibitor) and apixaban, rivaroxaban and edoxaban (direct factor Xa inhibitors), have been developed to overcome these issues. DOACs have shown promising results in Phase III clinical trials for post-operative VTE prophylaxis. This review summarises the pharmacological profile of DOACs and highlights the use of DOACs in post-operative VTE prophylaxis based on the available clinical trial data.